B. Metzler seel. Sohn & Co. AG Has $210.57 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

B. Metzler seel. Sohn & Co. AG decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 405,198 shares of the medical research company's stock after selling 6,092 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.2% of B. Metzler seel. Sohn & Co. AG's holdings, making the stock its 10th biggest holding. B. Metzler seel. Sohn & Co. AG owned 0.11% of Thermo Fisher Scientific worth $210,572,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of TMO. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after acquiring an additional 196,864 shares during the last quarter. State Street Corp grew its position in Thermo Fisher Scientific by 0.8% in the 3rd quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock worth $10,100,655,000 after purchasing an additional 124,996 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares during the period. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $3,149,754,000. Finally, Franklin Resources Inc. grew its holdings in Thermo Fisher Scientific by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock worth $2,935,377,000 after buying an additional 262,062 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Trading Down 3.9 %

Shares of TMO traded down $19.18 during midday trading on Thursday, hitting $469.88. The stock had a trading volume of 2,809,924 shares, compared to its average volume of 1,631,015. Thermo Fisher Scientific Inc. has a fifty-two week low of $468.39 and a fifty-two week high of $627.88. The business has a 50-day simple moving average of $536.85 and a two-hundred day simple moving average of $549.69. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market cap of $177.27 billion, a P/E ratio of 28.43, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.37%. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last 90 days. Company insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. UBS Group boosted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Scotiabank upped their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Raymond James reaffirmed an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.